A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

795

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Talquetamab
DRUG: Pomalidomide
DRUG: Teclistamab
DRUG: Elotuzumab
DRUG: Dexamethasone
DRUG: Bortezomib

Sponsor

Janssen Research & Development, LLC